Jointly Provided by AffinityCE and CheckRare CE

Supported by an educational grant from Xeris Pharmaceuticals, Inc and Recordati Rare Diseases, Inc.

Start date: January 31, 2023
End date: January 30, 2024
Estimated time to complete: 0.5 hours

NO LONGER AVAILABLE FOR CREDIT

Activity Description

This 30-minute CME program highlights the latest clinical research about Cushing’s disease and Cushing’s syndrome.

Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor that leads to excessive levels of cortisol. Cushing’s syndrome is also characterized by excessive levels of cortisol but can be due to a variety of reasons.

This CME program, hosted by Richard Auchus, MD, PhD Professor at the University of Michigan, provides an overview of the latest clinical research presented at ENDO 2022 involving Cushing’s disease and Cushing’s syndrome.

Faculty

Richard Auchus, MD, PhD
Professor
University of Michigan

Learning Objective

After participating in the activity, learners should be better able to:

• Describe the latest research being presented to better manage individuals with Cushing’s disease/syndrome and its clinical relevance.
• Share new information with their clinical team.

Disclosure Statement

AffinityCE and CheckRare CE staff, as well as planning and review committees, have no financial interests to disclose and do not recommend the use of products outside of the FDA approved labelling.

Faculty Educators

Dr. Auchus discloses the following relevant financial relationships with ineligible companies:

• Contracted research: Novartis Pharmaceuticals, Neurocrine Biosciences, Spruce Biosciences, Corcept Therapeutics, Sparrow Pharmaceuticals, Diurnal LTD.
• Consultant: Corcept Therapeutics, Novartis Pharmaceuticals, Neurocrine Biosciences, Quest Diagnostics, Janssen Pharmaceuticals, Xeris Pharmaceuticals, Crinetics Pharmaceuticals, Adrenas Therapeutics, PhaseBio Pharmaceuticals, Recordati Rare Diseases, Novo Nordisk, H Lunbeck A/S.

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 0.5 hours of AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Professionals

All other health care professionals completing this continuing education activity will be issued a Statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Commercial Support

Educational Support for this activity was provided by Xeris Pharmaceuticals, Inc and Recordati Rare Diseases, Inc.

Participation Costs

There is no cost to participate in this CME session. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.

CME Inquiries

For all CME policy-related inquiries, please contact us at [email protected].
Send customer support requests to [email protected].

Copyright

© 2023. This CME-certified activity is held as copyrighted © by AffinityCE and CheckRare CE. Through this notice, AffinityCE and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).